There’s been a delay to the planned expansion of an initiative that the European Medicines Agency says will help it compensate for the expected Brexit-related loss of UK expertise from the European pharmaceutical regulatory network. The broadening of the agency’s multinational assessment team (MNAT) concept from the pre- to the post-authorization phase was scheduled to start in April but is now due to begin in September.
The new start date is reported in the recently published minutes of the June meeting of the EMA’s main scientific committee, the CHMP. A new
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?